Literature DB >> 27903332

Computerized Cognitive Tests Are Associated with Biomarkers of Alzheimer's Disease in Cognitively Normal Individuals 10 Years Prior.

Anja Soldan1, Corinne Pettigrew1, Abhay Moghekar1, Marilyn Albert1.   

Abstract

OBJECTIVES: Evidence suggests that Alzheimer's disease (AD) biomarkers become abnormal many years before the emergence of clinical symptoms of AD, raising the possibility that biomarker levels measured in cognitively normal individuals would be associated with cognitive performance many years later. This study examined whether performance on computerized cognitive tests is associated with levels of cerebrospinal fluid (CSF) biomarkers of amyloid, tau, and phosphorylated tau (p-tau) obtained approximately 10 years earlier, when individuals were cognitively normal and primarily middle-aged.
METHODS: Individuals from the BIOCARD cohort (mean age at testing=69 years) were tested on two computerized tasks hypothesized to rely on brain regions affected by the early accumulation of AD pathology: (1) a Paired Associates Learning (PAL) task (n=67) and (2) a visual search task (n=86).
RESULTS: In regression analyses, poorer performance on the PAL task was associated with higher levels of CSF p-tau obtained years earlier, whereas worse performance in the visual search task was associated with lower levels of CSF Aβ1-42.
CONCLUSIONS: These findings suggest that AD biomarker levels may be differentially predictive of specific cognitive functions many years later. In line with the pattern of early accumulation of AD pathology, the PAL task, hypothesized to rely on medial temporal lobe function, was associated with CSF p-tau, whereas the visual search task, hypothesized to rely on frontoparietal function, was associated with CSF amyloid. Studies using amyloid and tau PET imaging will be useful in examining these hypothesized relationships further. (JINS, 2016, 22, 968-977).

Entities:  

Keywords:  Alzheimer’s disease; Amyloid; Cerebrospinal fluid; Cognition; Memory; Phosphorylated tau; Preclinical; Visual perception

Mesh:

Substances:

Year:  2016        PMID: 27903332      PMCID: PMC5154173          DOI: 10.1017/S1355617716000722

Source DB:  PubMed          Journal:  J Int Neuropsychol Soc        ISSN: 1355-6177            Impact factor:   2.892


  59 in total

1.  Abnormal visual search in mild cognitive impairment and Alzheimer's disease.

Authors:  Andrea Tales; Judy Haworth; Sara Nelson; Robert J Snowden; Gordon Wilcock
Journal:  Neurocase       Date:  2005-02       Impact factor: 0.881

2.  Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly.

Authors:  Anne M Fagan; Denise Head; Aarti R Shah; Daniel Marcus; Mark Mintun; John C Morris; David M Holtzman
Journal:  Ann Neurol       Date:  2009-02       Impact factor: 10.422

3.  Alzheimer disease biomarkers, attentional control, and semantic memory retrieval: Synergistic and mediational effects of biomarkers on a sensitive cognitive measure in non-demented older adults.

Authors:  Andrew J Aschenbrenner; David A Balota; Chi-Shing Tse; Anne M Fagan; David M Holtzman; Tammie L S Benzinger; John C Morris
Journal:  Neuropsychology       Date:  2014-09-15       Impact factor: 3.295

4.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

Authors:  Anne M Fagan; Catherine M Roe; Chengjie Xiong; Mark A Mintun; John C Morris; David M Holtzman
Journal:  Arch Neurol       Date:  2007-01-08

5.  Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.

Authors:  Courtney L Sutphen; Mateusz S Jasielec; Aarti R Shah; Elizabeth M Macy; Chengjie Xiong; Andrei G Vlassenko; Tammie L S Benzinger; Erik E J Stoops; Hugo M J Vanderstichele; Britta Brix; Heather D Darby; Manu L J Vandijck; Jack H Ladenson; John C Morris; David M Holtzman; Anne M Fagan
Journal:  JAMA Neurol       Date:  2015-09       Impact factor: 18.302

6.  Memory decline shows stronger associations with estimated spatial patterns of amyloid deposition progression than total amyloid burden.

Authors:  Rachel A Yotter; Jimit Doshi; Vanessa Clark; Jitka Sojkova; Yun Zhou; Dean F Wong; Luigi Ferrucci; Susan M Resnick; Christos Davatzikos
Journal:  Neurobiol Aging       Date:  2013-07-13       Impact factor: 4.673

7.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.

Authors:  Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters
Journal:  Lancet Neurol       Date:  2013-03-08       Impact factor: 44.182

8.  Visual search and the aging brain: discerning the effects of age-related brain volume shrinkage on alertness, feature binding, and attentional control.

Authors:  Eva M Müller-Oehring; Tilman Schulte; Torsten Rohlfing; Adolf Pfefferbaum; Edith V Sullivan
Journal:  Neuropsychology       Date:  2013-01       Impact factor: 3.295

9.  Biomarkers for predicting cognitive decline in those with normal cognition.

Authors:  Kyle Steenland; Liping Zhao; Felicia Goldstein; Janet Cellar; James Lah
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

10.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.

Authors:  Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2006-08-12       Impact factor: 17.088

View more
  2 in total

1.  Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease.

Authors:  Corinne Pettigrew; Anja Soldan; Kelly Sloane; Qing Cai; Jiangxia Wang; Mei-Cheng Wang; Abhay Moghekar; Michael I Miller; Marilyn Albert
Journal:  Neuroimage Clin       Date:  2017-08-25       Impact factor: 4.881

Review 2.  Biomarker-Based Signature of Alzheimer's Disease in Pre-MCI Individuals.

Authors:  Elena Chipi; Nicola Salvadori; Lucia Farotti; Lucilla Parnetti
Journal:  Brain Sci       Date:  2019-08-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.